Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GRI Bio ( (GRI) ) just unveiled an announcement.
On January 15, 2026, GRI Bio, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-30, with the final ratio and implementation left to the discretion of the board, and also approved the potential adjournment or postponement of the meeting if additional proxies were needed. The corporate actions followed a November 26, 2025 notice from Nasdaq that GRI Bio was not in compliance with the minimum stockholders’ equity requirement for continued listing, and the company’s subsequent completion on December 12, 2025 of an approximately $8 million best-efforts public offering of common stock and warrants, after which GRI Bio believes its stockholders’ equity exceeded the required $2.5 million threshold, though Nasdaq will continue to monitor compliance and the company could still face delisting risk if it falls short in future reporting periods.
The most recent analyst rating on (GRI) stock is a Hold with a $0.23 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn) and bearish technical trend/momentum. Valuation is constrained by unprofitable earnings and no dividend support. Offsetting these risks, recent corporate updates (positive Phase 2a data and new financing) provide incremental support but do not overcome the current financial and trend weakness.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a biotechnology company whose shares are listed on The Nasdaq Capital Market, operating in the public equity markets and subject to Nasdaq’s stockholders’ equity and listing requirements.
Average Trading Volume: 2,078,862
Technical Sentiment Signal: Sell
Current Market Cap: $3.32M
See more data about GRI stock on TipRanks’ Stock Analysis page.